HUTCHMED (China) Ltd (LSE: HCM) is a biopharmaceutical company focused on the discovery, development, and commercialisation of targeted therapies and immunotherapies for cancer and autoimmune diseases. With a strong R&D pipeline and operations across China and the US, HUTCHMED is advancing innovative treatments for global markets. Its integrated approach, from research to commercialisation, positions it as a key player in Asia’s growing biotech industry.
最新股票文章

2021-2025 年 Palantir 股票预测:IPO 上涨后是否还有进一步上涨空间?
您是否应该投资这家刚 IPO 不久的软件公司?继续阅读 Capital.com 的 Palantir 股价预测综述。
10:39, 20 二月 2025